Head and Neck TumorsHead and Neck TumorsОпухоли головы и шеи2222-14682411-4634Publishing House ABV Press7810.17650/2222-1468-2014-0-3-4-9DIAGNOSIS AND TREATMENT OF HEAD AND NECK TUMORSДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ ГОЛОВЫ И ШЕИCRITERIA OF WELL-DIFFERENTIATED THYROID CARCINOMA RESISTANCE TO RADIOIODINE THERAPYКРИТЕРИИ РЕЗИСТЕНТНОСТИ ВЫСОКОДИФФЕРЕНЦИРОВАННОГО РАКА ЩИТОВИДНОЙ ЖЕЛЕЗЫ К ТЕРАПИИ РАДИОАКТИВНЫМ ЙОДОМRumyantsevP. O.РумянцевП. О.
Russian Federation

Контакты: Павел Олегович Румянцев pavelrum@gmail.com

 

 

pavelrum@gmail.comFominD. K.ФоминД. К.
Russian Federation
pavelrum@gmail.comRumyantsevaU. V.РумянцеваУ. В.
Russian Federation
pavelrum@gmail.comEndocrinology Research Center, MoscowФГБУ «Эндокринологический научный центр» Минздрава России, МоскваRussian Research Center of Roentgen Radiology, MoscowФГБУ «Российский научный центр рентгенорадиологии» Минздрава России, Москва1504201443491804201518042015Copyright ©; 2014, Rumyantsev P.O., Fomin D.K., Rumyantseva U.V.Copyright ©; 2014, Румянцев П.О., Фомин Д.К., Румянцева У.В.2014Rumyantsev P.O., Fomin D.K., Rumyantseva U.V.Румянцев П.О., Фомин Д.К., Румянцева У.В.https://creativecommons.org/licenses/by/4.0https://ogsh.abvpress.ru/jour/article/view/78

In patients with well-differentiated thyroid cancer (WDTC) recurrence the metastatic tumor foci in numerous cases are not responded to radioiodine therapy which seriously deteriorate survival prognosis. In this article the contemporary evidential basis is analyzed so as to determine criteria of the resistance to radiodiodine therapy in inoperable WDTC patients.

При рецидиве высокодифференцированного рака щитовидной железы (ВДРЩЖ) метастатические опухолевые очаги далеко не всегда отвечают на терапию радиоактивным йодом, что резко ухудшает прогноз выживаемости. В статье анализируется современная доказательная база с целью определения критериев резистентности больных ВДРЩЖ к лечению радиоактивным йодом при резектабельном рецидиве опухоли.

thyroid cancerradioiodine therapyradioiodine-resistant metastasesmultikinase inhibitorssorafenibрак щитовидной железытерапия радиоактивным йодомрадиойодрезистентные метастазымультикиназные ингибиторысорафениб1. Румянцев П. О., Ильин А. А., Румянцева У. В., Саенко В. А. Рак щитовидной железы. Современные подходы к диагностике и лечению. М.: ГЭОТАР-Медиа, 2009. 448 с.Румянцев П. О., Ильин А. А., Румянцева У. В., Саенко В. А. Рак щитовидной железы. Современные подходы к диагностике и лечению. М.: ГЭОТАР-Медиа, 2009. 448 с.2. Cisco R. M., Shen W. T., Gosnell J. E. Extent of surgery for papillary thyroid cancer: preoperative imaging and role of prophylactic and therapeutic neck dissection. Curr Treat Options Oncol 2012;13(1):1–10.Cisco R. M., Shen W. T., Gosnell J. E. Extent of surgery for papillary thyroid cancer: preoperative imaging and role of prophylactic and therapeutic neck dissection. Curr Treat Options Oncol 2012;13(1):1–10.3. Pacini F., Schlumberger M., Dralle H. et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154(6):787–803.Pacini F., Schlumberger M., Dralle H. et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154(6):787–803.4. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper D. S., Doherty G. M., Haugen B. R. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19(11):1167–214.American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper D. S., Doherty G. M., Haugen B. R. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19(11):1167–214.5. Румянцев П. О., Коренев С. В., Румянцева У. В. Современные принципы терапии левотироксином после операции у больных высокодифференцированным раком щитовидной железы. Опухоли головы и шеи 2013;(2):5–8.Румянцев П. О., Коренев С. В., Румянцева У. В. Современные принципы терапии левотироксином после операции у больных высокодифференцированным раком щитовидной железы. Опухоли головы и шеи 2013;(2):5–8.6. Eustatia-Rutten C. F., Corssmit E. P., Biermasz N. R. et al. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006;91(1):313–9.Eustatia-Rutten C. F., Corssmit E. P., Biermasz N. R. et al. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006;91(1):313–9.7. Jonklaas J., Sarlis N. J., Litofsky D. et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006;16(12):1229–42.Jonklaas J., Sarlis N. J., Litofsky D. et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006;16(12):1229–42.8. Vrachimis A., Schober O., Riemann B. Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation. Nuklearmedizin 2012;51(3):67–72.Vrachimis A., Schober O., Riemann B. Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation. Nuklearmedizin 2012;51(3):67–72.9. Солодкий В. А., Фомин Д. К., Подольхова Н. В. и др. Радионуклидная терапия у больных дифференцированным раком щитовидной железы группы низкого риска прогрессирования. Вестник РНЦ рентгенорадиологии МЗ РФ 2012, http:// vestnik.rncrr.ru / vestnik / v12 / papers / fomin_ v12.htm.Солодкий В. А., Фомин Д. К., Подольхова Н. В. и др. Радионуклидная терапия у больных дифференцированным раком щитовидной железы группы низкого риска прогрессирования. Вестник РНЦ рентгенорадиологии МЗ РФ 2012, http:// vestnik.rncrr.ru / vestnik / v12 / papers / fomin_ v12.htm.10. Spitzweg C., Bible K. C., Hofbauer L. C., Morris J. C. Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets. Lancet Diabetes Endocrinol 2014 May 30.Spitzweg C., Bible K. C., Hofbauer L. C., Morris J. C. Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets. Lancet Diabetes Endocrinol 2014 May 30.11. Durante C., Haddy N., Baudin E. et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91(8):2892–9.Durante C., Haddy N., Baudin E. et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91(8):2892–9.12. Sabra M. M., Grewal R. K., Tala H. et al. Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans. Thyroid 2012;22(9):877–83.Sabra M. M., Grewal R. K., Tala H. et al. Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans. Thyroid 2012;22(9):877–83.13. Sgouros G., Kolbert K. S., Sheikh A. et al. Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med 2004;45(8):1366–72.Sgouros G., Kolbert K. S., Sheikh A. et al. Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med 2004;45(8):1366–72.14. Robbins R. J., Wan Q., Grewal R. K. et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxyD-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006;91(2):498–505.Robbins R. J., Wan Q., Grewal R. K. et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxyD-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006;91(2):498–505.15. Leboulleux S., El Bez I., Borget I. et al. Post-Radioiodine Treatment Whole Body Scan in the Era of Fluorodesoxyglucose Positron Emission Tomography for Differentiated Thyroid Carcinoma with elevated serum thyroglobulin levels. Thyroid 2012 Jun 5.Leboulleux S., El Bez I., Borget I. et al. Post-Radioiodine Treatment Whole Body Scan in the Era of Fluorodesoxyglucose Positron Emission Tomography for Differentiated Thyroid Carcinoma with elevated serum thyroglobulin levels. Thyroid 2012 Jun 5.16. Vaisman F., Tala H., Grewal R., Tuttle R. M. In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response. Thyroid 2011;21(12):1317–22.Vaisman F., Tala H., Grewal R., Tuttle R. M. In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response. Thyroid 2011;21(12):1317–22.17. Pacini F. Where do we stand with targeted therapy of refractory thyroid cancer? – Utility of RECIST criteria. Thyroid 2008;18(3):279–80.Pacini F. Where do we stand with targeted therapy of refractory thyroid cancer? – Utility of RECIST criteria. Thyroid 2008;18(3):279–80.18. Schlumberger M., Brose M., Elisei R. et al. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol 2014;2(5):356–8.Schlumberger M., Brose M., Elisei R. et al. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol 2014;2(5):356–8.19. Shimaoka K., Schoenfeld D. A., DeWys W.D. et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985;56(9):2155–60.Shimaoka K., Schoenfeld D. A., DeWys W.D. et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985;56(9):2155–60.20. Droz J. P., Schlumberger M., Rougier P. et al. Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy. Tumori 1990;76(5):480–3.Droz J. P., Schlumberger M., Rougier P. et al. Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy. Tumori 1990;76(5):480–3.21. Kloos R. T. Papillary thyroid cancer: medical management and follow-up. Curr Treat Options Oncol 2005;6(4):323–38.Kloos R. T. Papillary thyroid cancer: medical management and follow-up. Curr Treat Options Oncol 2005;6(4):323–38.22. Riesco-Eizaguirre G., Rodriguez I., De la Vieja A. et al. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res 2009;69(21):8317–25.Riesco-Eizaguirre G., Rodriguez I., De la Vieja A. et al. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res 2009;69(21):8317–25.23. Gao W. L., Wie L. L., Chao Y. G. et al. Prognostic prediction of BRAF(V600E) and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas. Clin Lab 2012;58(9–10):919–26.Gao W. L., Wie L. L., Chao Y. G. et al. Prognostic prediction of BRAF(V600E) and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas. Clin Lab 2012;58(9–10):919–26.24. Yang K., Wang H., Liang Z. et al. BRAFV600E mutation associated with nonradioiodine-avid status in distant metastatic papillary thyroid carcinoma. Clin Nucl Med 2014;39(8):675–9.Yang K., Wang H., Liang Z. et al. BRAFV600E mutation associated with nonradioiodine-avid status in distant metastatic papillary thyroid carcinoma. Clin Nucl Med 2014;39(8):675–9.25. Sabra M. M., Dominguez J. M., Grewal R. K. et al. Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases. J Clin Endocrinol Metab 2013;98(5):E829–36.Sabra M. M., Dominguez J. M., Grewal R. K. et al. Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases. J Clin Endocrinol Metab 2013;98(5):E829–36.26. D’Agostino M., Sponziello M., Puppin C. et al. Different expression of TSH receptor and NIS genes in thyroid cancer: role of epigenetics. J Mol Endocrinol 2014;52(2):121–31.D’Agostino M., Sponziello M., Puppin C. et al. Different expression of TSH receptor and NIS genes in thyroid cancer: role of epigenetics. J Mol Endocrinol 2014;52(2):121–31.27. Ho A. L., Grewal R. K., Leboeuf R. et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med 2013;368(7):623–32.Ho A. L., Grewal R. K., Leboeuf R. et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med 2013;368(7):623–32.28. Rothenberg S. M., McFadden D.S., Palmer E. et al. Re-differentiation of radioiodine-refractory BRAF V600E-mutant thryoid carcinoma with dabrafenib: a pilot study. J Clin Oncol (ASCO Meeting Abstracts) 2013;31:6023.Rothenberg S. M., McFadden D.S., Palmer E. et al. Re-differentiation of radioiodine-refractory BRAF V600E-mutant thryoid carcinoma with dabrafenib: a pilot study. J Clin Oncol (ASCO Meeting Abstracts) 2013;31:6023.29. Xing M., Haugen B. R., Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet 2013;381(9871):1058–69.Xing M., Haugen B. R., Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet 2013;381(9871):1058–69.30. Sacks W., Braunstein G. D. Evolving approaches in managing radioactive iodinerefractory differentiated thyroid cancer. Endocr Pract 2014;20(3):263–75.Sacks W., Braunstein G. D. Evolving approaches in managing radioactive iodinerefractory differentiated thyroid cancer. Endocr Pract 2014;20(3):263–75.